{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:13Z","timestamp":1785576973868,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1378\/chest.06-2042","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T15:45:47Z","timestamp":1173800747000},"page":"803-808","source":"Crossref","is-referenced-by-count":36,"title":["Hepatitis C Virus Infection and Hepatotoxicity During Antituberculosis Chemotherapy"],"prefix":"10.1016","volume":"131","author":[{"given":"Yong Soo","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jung","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee Young","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man Pyo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojoong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Jung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.06-2042_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement: global burden of tuberculosis; estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.06-2042_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"Treatment of tuberculosis","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-2042_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1183\/09031936.05.00103504","article-title":"Tuberculosis treatment outcomes in Europe: a systematic review","volume":"26","author":"Faustini","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.06-2042_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"10.1378\/chest.06-2042_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0962-8479(96)90098-2","article-title":"Liver injury during antituberculosis treatment: an 11-year study","volume":"77","author":"Dossing","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"10.1378\/chest.06-2042_bib6","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.06-2042_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-2042_bib8","first-page":"1499","article-title":"The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity","volume":"8","author":"Fernandez-Villar","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1378\/chest.06-2042_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","article-title":"A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B","volume":"12","author":"Hwang","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1378\/chest.06-2042_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0962-8479(93)90017-R","article-title":"Antituberculosis drug-induced hepatitis and HBsAg carriers","volume":"74","author":"Amarapurkar","year":"1993","journal-title":"Tuber Lung Dis"},{"key":"10.1378\/chest.06-2042_bib11","first-page":"1304","article-title":"Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"10.1378\/chest.06-2042_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1086\/323896","article-title":"Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis","volume":"33","author":"Sadaphal","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1378\/chest.06-2042_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fernandez-Villar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1378\/chest.06-2042_bib14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-2042_bib15","unstructured":"Annual report on the notified tuberculosis patients in Korea. Seoul [in Korean]. Republic of Korea: Korean Center for Disease Control and Prevention, 2006"},{"key":"10.1378\/chest.06-2042_bib16","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3346\/jkms.2005.20.6.985","article-title":"The prevalence of hepatitis C virus infection in Korea: pooled analysis","volume":"20","author":"Shin","year":"2005","journal-title":"J Korean Med Sci"},{"key":"10.1378\/chest.06-2042_bib17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-2042_bib18","first-page":"365","article-title":"Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983\u20131994","volume":"2","author":"Hong","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1378\/chest.06-2042_bib19","first-page":"912","article-title":"The treatment of tuberculosis in South Korea","volume":"7","author":"Seung","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1378\/chest.06-2042_bib20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1183\/09031936.95.08081384","article-title":"Anti-tuberculosis medication and the liver: dangers and recommendations in management","volume":"8","author":"Thompson","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.06-2042_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1572-0241.2003.07176.x","article-title":"Association between hepatitis C infection and other infectious diseases: a case for targeted screening?","volume":"98","author":"El-Serag","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1378\/chest.06-2042_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1440-1746.2004.03399.x","article-title":"Hepatitis C infection with history of tuberculosis in Japan: no association with progression of liver fibrosis","volume":"19","author":"Kanda","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1378\/chest.06-2042_bib23","first-page":"396","article-title":"High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia","volume":"10","author":"Richards","year":"2006","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215388978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215388978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:24:33Z","timestamp":1546979073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215388978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0012369215388978"],"URL":"https:\/\/doi.org\/10.1378\/chest.06-2042","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}